explore -WSS

explore

author：leisure time 2025-10-01 17:18:49 - browse：74

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： BD to buy Edwards patient monitoring unit for $4.2 billion

hotspot

WSS

An outdated Medicare rule harms dementia patients with anxiety

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

FDA greenlights medical device to combat bladder issues

Listen: Vivek Ramaswamy's star turn & leaky drug data

The most pressing bird flu mysteries scientists want answered

FTC loses bid to block Novant's North Carolina hospital merger

focus

explore

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

BD to buy Edwards patient monitoring unit for $4.2 billion

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Abortion policy in the spotlight at Republican debate

BioMarin wins approval for gene therapy to treat hemophilia A

Intellia plays down concerns on accidental germline transmission

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Peter Hotez and the public health issue of online harassment

Roche's accidental data boosts hopes for anti

explore

CMS got Medicare Advantage quality rating wrong, judge rules

Vivek Ramaswamy made waves in the debate, much as in biotech

Trans patients at the end of life deserve respect and dignity

Finland to offer bird flu vaccine to select groups of people, a possible global first

Stopping antidepressants leads to symptoms for 1 in 6 patients

CMS got Medicare Advantage quality rating wrong, judge rules

knowledge

hotspot

explore

knowledge